New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm

Journal of Medicinal Chemistry
Eric Valeur, Patrick Jimonet

Abstract

With the rise of novel biology and high potential target identification technologies originating from advances in genomics, medicinal chemists are progressively facing targets of increasing complexity and often unprecedented. Novel hit finding technologies, combined with a wider choice of drug modalities, has resulted in a unique repertoire of options to address these challenging targets and to identify suitable starting points for optimization. Furthermore, innovative solutions originating from a range of academic groups and biotech companies require new types of collaborative models to leverage and integrate them in the drug discovery process. This perspective provides a guide for medicinal chemists covering contemporary probe and lead generation approaches and discusses the strengths and limitations of each strategy. Moreover, the expansion of strategies to modulate proteins creates the opportunity of a modality-agnostic and mode-of-action centric hit finding paradigm.

References

Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S Brenner, R A Lerner
Jan 1, 1996·Medicinal Research Reviews·R S BohacekW C Guida
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·K McMillanJ J Devlin
Mar 21, 2003·Journal of Medicinal Chemistry·Mark C WenlockPaul D Leeson
Jan 27, 2007·Journal of Computer-aided Molecular Design·Richard D CramerBrian Campbell
Dec 21, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gregory L Verdine, Loren D Walensky
Apr 3, 2008·Journal of Medicinal Chemistry·Markus BoehmChristian Lemmen
Apr 17, 2008·Accounts of Chemical Research·John A Robinson
Apr 11, 2009·ChemMedChem·Michael J StocksJeffrey P Stonehouse
May 13, 2009·Journal of Chemical Information and Modeling·Uta LesselHolger Claussen
Jun 2, 2009·Nature Chemical Biology·Christian HeinisGreg Winter
Aug 12, 2009·Molecular BioSystems·Andrea L Jochim, Paramjit S Arora
Oct 1, 2009·Journal of Chemical Information and Modeling·Willem P van Hoorn, Andrew S Bell
Nov 13, 2009·Nature·Raymond E MoelleringJames E Bradner
Feb 20, 2010·Science·Nityakalyani SrinivasJohn A Robinson
Aug 18, 2010·ACS Chemical Biology·Andrea L Jochim, Paramjit S Arora
Jan 14, 2011·Nature·Søren G F RasmussenBrian K Kobilka
Mar 2, 2011·Nature Reviews. Drug Discovery·Ricardo MacarronG Sitta Sittampalam
Jun 22, 2011·Proceedings of the National Academy of Sciences of the United States of America·Travis S YoungPeter G Schultz
Jun 28, 2011·Nature Chemical Biology·Andrew C StelzerHashim M Al-Hashimi
Jul 21, 2011·Nature·Søren G F RasmussenBrian K Kobilka
Jul 27, 2011·Chemical Society Reviews·Gavin W Collie, Gary N Parkinson
Sep 24, 2011·Expert Opinion on Biological Therapy·Glenn F King
Oct 1, 2011·Nature Reviews. Drug Discovery·Paul D Leeson, Stephen A St-Gallay
Dec 30, 2011·Current Pharmaceutical Design·Markus MuttenthalerPaul F Alewood
Mar 22, 2012·The Journal of Biological Chemistry·Cathy PoillotMichel De Waard
Apr 12, 2012·Chembiochem : a European Journal of Chemical Biology·Shiyu ChenChristian Heinis
May 11, 2012·Current Topics in Medicinal Chemistry·Devon L RamsayGary W Caldwell
Jun 5, 2012·Journal of Chemical Information and Modeling·Mikko J VainioFlorian Raubacher
Oct 17, 2012·Proceedings of the National Academy of Sciences of the United States of America·Tom N GrossmannGregory L Verdine
Mar 20, 2013·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Kenichiro ItoHiroaki Suga
May 1, 2013·Nature Reviews. Drug Discovery·Kim Lewis
Jun 26, 2013·Journal of the American Chemical Society·Elena MirandaAli Tavassoli
Jul 16, 2013·Journal of the American Chemical Society·Yanbin JiJulio A Camarero
Sep 21, 2013·Journal of Medicinal Chemistry·Fabrizio Giordanetto, Jan Kihlberg
Sep 21, 2013·Drug Discovery Today. Technologies·Zhengwei Peng
Dec 21, 2013·Science·Wei LiuVadim Cherezov
Feb 15, 2014·Nature Communications·Uwe WeierstallVadim Cherezov
Mar 4, 2014·Nature Biotechnology·Jeffry D Sander, J Keith Joung

❮ Previous
Next ❯

Citations

Oct 24, 2019·Current Topics in Medicinal Chemistry·Liwen XiaYongtao Duan
Jan 17, 2019·Current Drug Discovery Technologies·Martin Braddock
Dec 5, 2019·The Journal of the Acoustical Society of America·Rick P C Cousins
Nov 2, 2019·MedChemComm·Eric ValeurAlleyn T Plowright
Dec 5, 2020·Future Medicinal Chemistry·Daniel ConoleMichael J Waring
May 5, 2021·The AAPS Journal·Jing ShiFrancis L S Tse
Jan 5, 2021·Journal of the American Society for Mass Spectrometry·Zhe ZhangYang Yang
Feb 6, 2019·Journal of Medicinal Chemistry·Quinn CoughlinDario Doller
Nov 18, 2018·Journal of the American Chemical Society·Philipp M CrommCraig M Crews
Nov 11, 2020·ACS Combinatorial Science·Sabrina E IskandarAlbert A Bowers
Jun 23, 2020·ACS Chemical Biology·Andrei UrsuMatthew D Disney
Mar 28, 2020·Journal of Medicinal Chemistry·Matthew G CostalesMatthew D Disney
Oct 16, 2020·ACS Infectious Diseases·Shashank KulkarniThomas Spangenberg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved